{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:03:53Z","timestamp":1793642633239,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Ministry of Trade, Industry & Energy","award":["20003883"],"award-info":[{"award-number":["20003883"]}]},{"name":"the Ministry of Health &Welfare,South Korea","award":["HR16C0001"],"award-info":[{"award-number":["HR16C0001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Child Adolesc Psychiatry Ment Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Methylphenidate (MPH) is the most frequently prescribed medication for the treatment of attention deficit hyperactivity disorder (ADHD). However, the safety of its long-term use remain unclear. In particular, real-world evidence of long-term MPH treatment regarding the risk of depression, conduct disorders, and psychotic disorders in children and adolescents is needed. This study aimed to compare the risks of depression, conduct disorder, and psychotic disorder between long- and short-term MPH treatments in children and adolescents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This population-based cohort study used a nationwide claims database of all patients with ADHD in South Korea. Patients aged less than 18\u00a0years who were prescribed MPH were included in the study. Long- and short-term MPH were defined as\u2009&gt;\u20091\u00a0year, and\u2009&lt;\u20091\u00a0year, respectively. Overall, the risk of developing depressive disorder, conduct disorder and oppositional defiant disorder (ODD), and psychotic disorder were investigated. A 1:2 propensity score matching was used to balance the cohorts, and the Cox proportional hazards model was used to evaluate the safety of MPH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 1309 long-term and 2199 short-term MPH users. Long-term MPH use was associated with a significantly lower risk of depressive (hazard ratio [HR], 0.70 [95% confidence interval [CI] 0.55\u20130.88]) and conduct disorders and ODD (HR, 0.52 [95% CI 0.38\u20130.73]) than short-term MPH use. Psychotic disorder was not significantly associated with long-term MPH use (hazard ratio [HR], 0.83 [95% confidence interval [CI] 0.52\u20131.32]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that long-term MPH use may be associated with a decreased risk of depression, conduct disorders and ODD. Moreover, the long-term use of MPH does not increase the risk of psychotic disorders. Long-term MPH administration may be considered as a favourable treatment strategy for children and adolescents with ADHD regarding depressive, conduct, and psychotic disorders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13034-022-00515-5","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T17:05:55Z","timestamp":1665507955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-term methylphenidate use for children and adolescents with attention deficit hyperactivity disorder and risk for depression, conduct disorder, and psychotic disorder: a nationwide longitudinal cohort study in South Korea"],"prefix":"10.1186","volume":"16","author":[{"given":"Jimyung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeewon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae Woong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmi","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"issue":"11","key":"515_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/00004583-200111000-00008","volume":"40","author":"CL Bagwell","year":"2001","unstructured":"Bagwell CL, Molina BS, Pelham WE Jr, et al. Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry. 2001;40(11):1285\u201392.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"515_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2016.07.774","author":"L Hechtman","year":"2016","unstructured":"Hechtman L, Swanson JM, Sibley MH, et al. Functional adult outcomes 16 years after childhood diagnosis of attention-deficit\/hyperactivity disorder: MTA results. J Am Acad Child Adolesc Psychiatry. 2016. https:\/\/doi.org\/10.1016\/j.jaac.2016.07.774.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"515_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1176\/appi.ajp.2021.21010032","volume":"179","author":"MH Sibley","year":"2022","unstructured":"Sibley MH, Arnold LE, Swanson JM, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. Am J Psychiatry. 2022;179(2):142\u201351.","journal-title":"Am J Psychiatry."},{"key":"515_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2022.03.030","author":"MM Cordova","year":"2022","unstructured":"Cordova MM, Antovich DM, Ryabinin P, et al. Attention-deficit\/hyperactivity disorder restricted phenotypes prevalence, comorbidity, and polygenic risk sensitivity in the ABCD baseline cohort. J Am Acad Child Adolesc Psychiatry. 2022. https:\/\/doi.org\/10.1016\/j.jaac.2022.03.030.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"515_CR5","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.03","author":"WB Daviss","year":"2008","unstructured":"Daviss WB. A review of co-morbid depression in pediatric ADHD: Etiologies, phenomenology, and treatment. J child Adolesc Psychopharmacol. 2008. https:\/\/doi.org\/10.1089\/cap.2008.03.","journal-title":"J child Adolesc Psychopharmacol"},{"key":"515_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugalcdep.2014.11.018","volume":"147","author":"WB Brinkman","year":"2015","unstructured":"Brinkman WB, Epstein JN, Auinger P, et al. Association of attention-deficit\/hyperactivity disorder and conduct disorder with early tobacco and alcohol use. Drug Alcohol Depend. 2015;147:183\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"515_CR7","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","volume":"46","author":"S Pliszka","year":"2007","unstructured":"Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894\u2013921.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"515_CR8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2528","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019. https:\/\/doi.org\/10.1542\/peds.2019-2528.","journal-title":"Pediatrics"},{"key":"515_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101524","volume":"50","author":"S Brumbaugh","year":"2022","unstructured":"Brumbaugh S, Tuan WJ, Scott A, et al. Trends in characteristics of the recipients of new prescription stimulants between years 2010 and 2020 in the United States: an observational cohort study. EClinicalMedicine. 2022;50: 101524.","journal-title":"EClinicalMedicine"},{"key":"515_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-022-02034-2","author":"AM S\u00f8rensen","year":"2022","unstructured":"S\u00f8rensen AM, Wesselh\u00f6ft R, Andersen JH, et al. Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010\u20132020. Eur Child Adolesc Psychiatry. 2022. https:\/\/doi.org\/10.1007\/s00787-022-02034-2.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"515_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1403494820901426","volume":"48","author":"M Vuori","year":"2020","unstructured":"Vuori M, Koski-Piril\u00e4 A, Martikainen JE, et al. Gender-and age-stratified analyses of ADHD medication use in children and adolescents in Finland using population-based longitudinal data, 2008\u20132018. Scand J Public Health. 2020;48(3):303\u20137.","journal-title":"Scand J Public Health"},{"key":"515_CR12","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1001\/jama.2016.3427","volume":"315","author":"P Shaw","year":"2016","unstructured":"Shaw P. Quantifying the benefits and risks of methylphenidate as treatment for childhood attention-deficit\/hyperactivity disorder. JAMA. 2016;315:1953\u20135.","journal-title":"JAMA"},{"issue":"6","key":"515_CR13","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1111\/bcp.13544","volume":"84","author":"V Pauly","year":"2018","unstructured":"Pauly V, Frauger E, Lepelley M, et al. Patterns and profiles of methylphenidate use both in children and adults. Br J Clin Pharmacol. 2018;84(6):1215\u201327.","journal-title":"Br J Clin Pharmacol"},{"key":"515_CR14","unstructured":"(EMEA) TEMA. Methylphenidate article 31 referral\u2014annex I, II, III, IV. 2007."},{"key":"515_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.neubiorev.2019.09.023","volume":"107","author":"H Krinzinger","year":"2019","unstructured":"Krinzinger H, Hall CL, Groom MJ, et al. Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: a map of the current evidence. Neurosci Biobehav Rev. 2019;107:945\u201368.","journal-title":"Neurosci Biobehav Rev"},{"issue":"06","key":"515_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/a-1207-9851","volume":"53","author":"B Kis","year":"2020","unstructured":"Kis B, L\u00fccke C, Abdel-Hamid M, et al. Safety profile of methylphenidate under long-term treatment in adult ADHD patients-results of the compas study. Pharmacopsychiatry. 2020;53(06):263\u201371.","journal-title":"Pharmacopsychiatry"},{"key":"515_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/1087054719886372","author":"MR Mohammadi","year":"2021","unstructured":"Mohammadi MR, Zarafshan H, Khaleghi A, et al. Prevalence of ADHD and its comorbidities in a population-based sample. J Atten Disord. 2021. https:\/\/doi.org\/10.1177\/1087054719886372.","journal-title":"J Atten Disord"},{"key":"515_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.216","author":"KK Man","year":"2016","unstructured":"Man KK, Coghill D, Chan EW, et al. Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry. 2016. https:\/\/doi.org\/10.1038\/tp.2016.216.","journal-title":"Transl Psychiatry"},{"issue":"4","key":"515_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00127-018-1615-x","volume":"54","author":"MH Lee","year":"2019","unstructured":"Lee MH, Choi JW, Lee J, et al. Trends in prescriptions for sedative\u2013hypnotics among Korean adults: a nationwide prescription database study for 2011\u20132015. Soc Psychiatry Psychiatr Epidemiol. 2019;54(4):477\u201384.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"16","key":"515_CR20","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2020.16167","volume":"324","author":"SC You","year":"2020","unstructured":"You SC, Rho Y, Bikdeli B, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324(16):1640\u201350.","journal-title":"JAMA"},{"key":"515_CR21","first-page":"574","volume":"216","author":"G Hripcsak","year":"2015","unstructured":"Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574.","journal-title":"Stud Health Technol Inform"},{"issue":"1","key":"515_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaac.2021.03.019","volume":"61","author":"AC Childress","year":"2022","unstructured":"Childress AC, Foehl HC, Newcorn JH, et al. Long-Term Treatment With Extended-Release Methylphenidate Treatment in Children Aged 4 to< 6 Years. J Am Acad Child Adolesc Psychiatry. 2022;61(1):80\u201392.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"515_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4980","author":"AP Lam","year":"2019","unstructured":"Lam AP, Matthies S, Graf E, et al. Long-term effects of multimodal treatment on adult attention-deficit\/hyperactivity disorder symptoms: follow-up analysis of the COMPAS trial. JAMA Netw Open. 2019. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.4980.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"515_CR24","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/ije\/dyy120","volume":"47","author":"Y Tian","year":"2018","unstructured":"Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005\u201314.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"515_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.biopsych.2019.04.009","volume":"86","author":"Z Chang","year":"2019","unstructured":"Chang Z, Ghirardi L, Quinn PD, et al. Risks and benefits of ADHD medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry. 2019;86(5):335.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"515_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/cap.2007.0100","volume":"18","author":"WB Daviss","year":"2008","unstructured":"Daviss WB, Birmaher B, Diler RS, et al. Does pharmacotherapy for attention-deficit\/hyperactivity disorder predict risk of later major depression? J Child Adolesc Psychopharmacol. 2008;18(3):257\u201364.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"515_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1542\/peds.2008-3347","volume":"124","author":"J Biederman","year":"2009","unstructured":"Biederman J, Monuteaux MC, Spencer T, et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics. 2009;124(1):71\u20138.","journal-title":"Pediatrics"},{"key":"515_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jad.2015.09.015","volume":"189","author":"MJ Lee","year":"2016","unstructured":"Lee MJ, Yang KC, Shyu YC, et al. Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population-based study in Taiwan. J Affect Disord. 2016;189:110\u20137.","journal-title":"J Affect Disord"},{"issue":"12","key":"515_CR29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.biopsych.2016.02.018","volume":"80","author":"Z Chang","year":"2016","unstructured":"Chang Z, D\u2019Onofrio BM, Quinn PD, et al. Medication for attention-deficit\/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiat. 2016;80(12):916\u201322.","journal-title":"Biol Psychiat"},{"issue":"7","key":"515_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/01.chi.0000128796.84202.eb","volume":"43","author":"L Hechtman","year":"2004","unstructured":"Hechtman L, Abikoff H, Klein RG, et al. Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43(7):812\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"21","key":"515_CR31","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","volume":"367","author":"P Lichtenstein","year":"2012","unstructured":"Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit\u2013hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006\u201314.","journal-title":"N Engl J Med"},{"issue":"6","key":"515_CR32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1001\/jamapsychiatry.2017.0659","volume":"74","author":"Z Chang","year":"2017","unstructured":"Chang Z, Quinn PD, Hur K, et al. Association between medication use for attention-deficit\/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry. 2017;74(6):597\u2013603.","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"515_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/jcpp.12164","volume":"55","author":"Z Chang","year":"2014","unstructured":"Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014;55(8):878\u201385.","journal-title":"J Child Psychol Psychiatry"},{"key":"515_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/070674371506000202","author":"T Pringsheim","year":"2015","unstructured":"Pringsheim T, Hirsch L, Gardner D, et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015. https:\/\/doi.org\/10.1177\/070674371506000202.","journal-title":"Can J Psychiatry"},{"issue":"12","key":"515_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.biopsych.2007.04.009","volume":"61","author":"SR Chamberlain","year":"2007","unstructured":"Chamberlain SR, Robbins TW, Sahakian BJ. The neurobiology of attention-deficit\/hyperactivity disorder. Biol Psychiat. 2007;61(12):1317\u20139.","journal-title":"Biol Psychiat"},{"issue":"9","key":"515_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/1087054714538655","volume":"21","author":"B Bendiksen","year":"2017","unstructured":"Bendiksen B, Svensson E, Aase H, et al. Co-occurrence of ODD and CD in preschool children with symptoms of ADHD. J Atten Disord. 2017;21(9):741\u201352.","journal-title":"J Atten Disord"},{"issue":"2","key":"515_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00004583-200102000-00009","volume":"40","author":"PS Jensen","year":"2001","unstructured":"Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001;40(2):147\u201358.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"515_CR38","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/WNF.0b013e3181e29174","volume":"33","author":"M Kraemer","year":"2010","unstructured":"Kraemer M, Uekermann J, Wiltfang J, et al. Methylphenidate-induced psychosis in adult attention-deficit\/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol. 2010;33(4):204\u20136.","journal-title":"Clin Neuropharmacol"},{"issue":"1\u20132","key":"515_CR39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.schres.2015.08.033","volume":"168","author":"Y-C Shyu","year":"2015","unstructured":"Shyu Y-C, Yuan S-S, Lee S-Y, et al. Attention-deficit\/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population-based study in Taiwan. Schizophr Res. 2015;168(1\u20132):161\u20137.","journal-title":"Schizophr Res"},{"issue":"1","key":"515_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-022-03689-6","volume":"22","author":"H Kim","year":"2022","unstructured":"Kim H, Jeong W, Kim SH, et al. Association between social phobia and the risk of arrhythmia using the Korean national sample cohort: a retrospective cohort study. BMC Psychiatry. 2022;22(1):1\u20138.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"515_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1192\/bjp.2018.8","volume":"212","author":"KL Huang","year":"2018","unstructured":"Huang KL, Wei HT, Hsu JW, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. Br J Psychiatry. 2018;212(4):234\u20138.","journal-title":"Br J Psychiatry"},{"key":"515_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ridd.2017.10.023","volume":"72","author":"SH Liang","year":"2018","unstructured":"Liang SH, Yang YH, Kuo TY, et al. Suicide risk reduction in youths with attention-deficit\/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study. Res Dev Disabil. 2018;72:96\u2013105.","journal-title":"Res Dev Disabil"},{"issue":"2","key":"515_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11682-017-9707-x","volume":"12","author":"A Schrantee","year":"2018","unstructured":"Schrantee A, Bouziane C, Bron EE, et al. Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder. Brain Imaging Behav. 2018;12(2):402\u201310.","journal-title":"Brain Imaging Behav"}],"container-title":["Child and Adolescent Psychiatry and Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-022-00515-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13034-022-00515-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-022-00515-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T04:04:28Z","timestamp":1665547468000},"score":1,"resource":{"primary":{"URL":"https:\/\/capmh.biomedcentral.com\/articles\/10.1186\/s13034-022-00515-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1186\/s13034-022-00515-5","relation":{},"ISSN":["1753-2000"],"issn-type":[{"value":"1753-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This rertospective cohort study using nationwide claims database was approved by the Institutional Review Board of the Ajou University Hospital (IRB number: AJIRB-MED-EXP-21-088), and the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}